Document:

v152835_ex4-7 -- Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing

    Exhibit
4.7Exhibit
4.16

    

     

    EXCLUSIVE
TESTING AND ADMINISTRATIVE SERVICES AGREEMENT

     

    between

     

    ROSETTA
GENOMICS LTD.

    A limited
liability company under the laws of Israel,

    of 10
Plaut St., Rehovot, Israel, 76706

    (“Rosetta”)

     

    and

     

    TEVA
PHARMACEUTICAL INDUSTRIES LTD.

    of P.O.
Box 3190 Petah-Tiqua 49131, Israel

     

    
      THIS EXCLUSIVE TESTING AND
ADMINISTRATIVE SERVICES AGREEMENT (this “Agreement”) is made as of the
24th day of December, 2008, by and between: Rosetta, Ltd., through its offices
located at 10 Plaut St., Rehovot, Israel, 76706 (“Rosetta”); and Teva
Pharmaceutical Industries Ltd., through its offices located at 12 Hatrufa St.,
Netanya, Israel (“Teva”).

       

    

    
      	
              WHERESA

            	
              Rosetta
      has developed the Tests (as such term is hereinafter defined), and is
      intending to initiate the offering of the Testing Services to patients
      through physicians worldwide;

            

    

     

    
      	
              WHEREAS

            	
              Rosetta
      desires that its Testing Services be made available to patients and
      physicians in the Territory (as hereinafter defined) and that Teva assist
      Rosetta in that effort by and the Administrative Services (as such terms
      is hereinafter defined) for and on behalf of Rosetta in and for the
      Territory;

            

    

     

    
      	
              WHEREAS

            	
              Teva
      desires to exclusively market and purchase Testing Services from Rosetta
      and exclusively provide certain Administrative Services for and on behalf
      of Rosetta in and for the
Territory;

            

    

     

    
      	
              WHEREAS

            	
              Rosetta
      will exclusively in and for the Territory provide the Testing Services
      ordered by Teva;

            

    

     

    
      	
              WHEREAS

            	
              Teva
      agrees to pay Rosetta for Testing Services ordered by Teva in accordance
      with the fees identified in Section 7
herein.

            

    

     

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    NOW
THEREFORE THE PARTIES AGREE AS FOLLOWS:

     

    1.           INTERPRETATION AND
DEFINITIONS

     

    
      	
               
      

            	
              1.1

            	
              The
      preamble to this Agreement forms an integral part hereof and is
      incorporated herein by reference.

            

    

     

    
      	
               
      

            	
              1.2

            	
              Clause
      headings in this Agreement are intended solely for convenience of
      reference and shall be given no effect in the interpretation of this
      Agreement.

            

    

     

    
      	
               
      

            	
              1.3

            	
              All
      signed appendices to this Agreement, whether attached at the time of
      signature hereof or at any time thereafter, shall be construed as an
      integral part of this Agreement.

            

    

     

    
      	
               
      

            	
              1.4

            	
              In
      this Agreement, the following expressions shall bear the meanings assigned
      to them below and cognate expressions shall bear corresponding
      meanings:

            

    

     

    
      	
               
      

            	
              1.4.1

            	
              "Administrative Services"
      – shall mean the sole and exclusive marketing sale and distribution and
      logistic services solely provided by Teva with respect to the Tests, all
      as detailed in clause 4.

            

    

     

    
      	
               
      

            	
              1.4.2

            	
              “Affiliate” - with
      respect to either party, means any person, corporation, company,
      partnership or other entity controlling, controlled by or under common
      control with such party. For such purpose the term “control” means the
      holding of 50% or more of the common voting stock or ordinary shares in,
      or the right to appoint 50% or more of the directors of, the said
      corporation, company, partnership or
entity.

            

    

     

    
      	
               
      

            	
              1.4.3

            	
              “Business Day”- shall
      mean working days, not including Saturdays and Sundays and/or public
      holidays and bank holidays in the US and
Israel.

            

    

     

    
      	
               
      

            	
              1.4.4

            	
              “Effective Date” – shall
      mean the date of signature of this Agreement by the last of the
      parties.

            

    

     

    
      	
               
      

            	
              1.4.5

            	
              “Instructions” – shall
      mean the written instructions provided to Teva by Rosetta with respect to
      the receipt of samples from its patients and physicians, shipment and
      delivery of samples for testing, provide customers with the Testing
      Services written reports and results, as provided by
    Rosetta.

            

    

     

    
      	
               
      

            	
              1.4.6

            	
              “Territory” – shall mean
      Israel and Turkey. For the purpose of clarity, Israel and Turkey shall be
      regarded as separate territories, and termination in relation to the
      Turkey Territory (according to the terms of section 8) shall not affect
      the Israeli Territory. In case of termination in relation to the Israeli
      Territory the entire Agreement will be terminated unless otherwise agreed
      in writing by the parties.

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              1.4.7

            	
              “Tests” – "miRviewTM
      squamous", "miRviewTM meso" and "miRviewTM mets", as conducted by Rosetta
      or, its Affiliated and/or other third parties on behalf of Rosetta subject
      to the provisions of Section 5.1.

            

    

     

    
      	
               
      

            	
              1.4.8

            	
              "Testing Services” - as
      provided by Rosetta, its Affiliates and/or other third parties on behalf
      of Rosetta subject to the provisions of Section 5.1 shall include the
      conduct of the Tests, the provision of Test reports and results to Teva,
      and the return of the paraffin blocks, when supplied. It is agreed by both
      parties that other oncology testing services may be added to the above
      definition upon agreement of the parties in
  writing.

            

    

     

    
      	
               
      

            	
              1.4.9

            	
              "Samples" – paraffin
      embedded tissues and/or unstained slides processed from paraffin embedded
      tissues provided from pathologists from different medical
      institutions.

            

    

     

    2.           APPOINTMENT AND
DURATION

     

    
      	
               
      

            	
              2.1

            	
              Rosetta
      hereby appoints Teva as an exclusive reseller of the Testing Services and
      the provider of the Administrative Services in and for the Territory in
      accordance with the terms of this Agreement, and Teva accepts such
      appointment.

            

    

     

    
      	
               
      

            	
              2.2

            	
              This
      Agreement shall commence on the Effective Date and, unless terminated
      earlier in accordance with Clause 8 below, shall continue for an initial
      term of 24 months ("The
      Term"). The Term shall be automatically renewed for an additional
      periods of 12 months each unless either party gives a prior written notice
      of its intention not to renew the agreement not later than 3 months before
      any renewal.

            

    

     

    
      	
               
      

            	
              2.3

            	
              Teva
      shall be entitled at any time during the term of this Agreement in its
      absolute discretion to cease the resale or marketing of the Testing
      Services in the Territory (whole or part) for reasons of medical safety or
      on legal or regulatory grounds; if Teva ceases resale or marketing of the
      Testing Services pursuant to this Section 2.3 for a period exceeding three
      (3) months then Rosetta shall have the right to terminate this Agreement
      by providing Teva a ten (10) days prior written notice
  .

            

    

     

    
      	
               
      

            	
              2.4

            	
              Rosetta
      shall be entitled at any time during the term of this Agreement in its
      absolute discretion to cease providing Testing Services to Teva, in whole
      or in part, for reasons of medical safety or on legal or regulatory
      grounds.

            

    

     

    3.           REGISTRATION

     

    Within 60
days after the Effective Date, Rosetta undertakes to provide Teva with copies of
Rosetta’s CAP and CLIA licenses and certificates. In addition, at Teva’s
request, Rosetta will provide Teva with one copy of other existing and readily
available documentation to the extent required by Teva for any and all
regulatory purposes.

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    4.           ADMINISTRATIVE
SERVICES

     

    Teva
undertakes and agrees with effect from the Effective Date and at all subsequent
times during the term of this Agreement, in connection with the provision of
Administrative Services for and on behalf of Rosetta:

     

    
      	
               
      

            	
              4.1

            	
              to
      use all reasonable endeavours to market the Testing Services in the
      Territory subject to the terms and conditions of this Agreement and to
      perform at its own expense, all tasks and duties and assume all
      responsibilities customarily associated with marketing of the Testing
      Services;

            

    

     

    
      	
               
      

            	
              4.2

            	
              to
      market Testing Services only from Rosetta, subject to Rosetta’s ability to
      carry out the Testing Services in accordance with this Agreement, all
      pursuant to section 2.3 herein;

            

    

     

    
      	
               
      

            	
              4.3

            	
              further
      to marketing the Testing Services, Teva shall be responsible for the
      receipt of samples in accordance with Instructions from its customers,
      shipment and delivery of the Testing Services kit according to the
      Instructions to Rosetta for testing, and upon completion of testing, to
      provide its customers the Testing Services written reports and results, as
      provided by Rosetta, according to the
  Instructions.

            

    

     

    
      	
               
      

            	
              4.4

            	
              to
      obtain and maintain all government licenses, approvals and permissions
      necessary in connection with the marketing, resale and provision of the
      Testing Services to persons in the
Territory;

            

    

     

    
      	
               
      

            	
              4.5

            	
              to
      inform Rosetta of any matter in the Territory of which it is aware that is
      likely to affect, significantly, the marketing of the Testing
      Services;

            

    

     

    
      	
               
      

            	
              4.6

            	
              to
      provide Rosetta with market and sales information in a timely fashion
      including information relating to the sales and marketing activities of
      Teva with respect to the Testing
Services,;

            

    

     

    
      	
               
      

            	
              4.7

            	
              to
      handle all physician, patient and other inquiries, whether via telephone
      or in writing, regarding Rosetta’s provision of Testing Services,
      including information relating to the results of such Testing
      Services;

            

    

     

    
      	
               
      

            	
              4.8

            	
              to
      inform Rosetta of any reports of irregularities, complaints or other
      adverse information received by Teva relating to the Tests, its use or
      quality and/or the Testing Services, and not to take any action with
      regard thereto, unless required by law or the regulatory authorities in
      the Territory, without obtaining Rosetta’s prior written consent, such
      consent to be provided promptly and not unreasonably withheld by
      Rosetta;

            

    

     

    
      	
               
      

            	
              4.9

            	
              to
      conduct its marketing activities in a manner that reflects favorably at
      all times on the Testing Services and the name, goodwill and reputation of
      Rosetta; to refrain from engaging in deceptive, misleading or unethical
      practices,
      including but not limited to, disparagement of Rosetta or the Testing
      Services, and acceptance or payment of bribes, kickbacks or secret
      profits; to make no representations, warranties, guarantees or covenants,
      with respect to the Testing Services, other than those set forth in the
      Promotional Materials, as defined thereafter, provided to Teva by Rosetta;
      and not to modify any Promotional Materials without Rosetta’s prior
      written consent;

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    
    

     

    
      	
               
      

            	
              4.10

            	
              not
      to modify in any manner whatsoever the Test reports and results or
      disclaimers associated with such
reports;

            

    

     

    
      	
               
      

            	
              4.11

            	
              unless
      otherwise mutually agreed in writing, to be solely responsible for all
      expenses, costs, liabilities and obligations Teva incurs in connection
      with its resale of the Testing Services and the provision of the
      Administrative Services identified
herein.

            

    

     

    5.           ROSETTA’S
UNDERTAKINGS

     

    Rosetta
undertakes and agrees with effect from the Effective Date and at all subsequent
times during the term of this Agreement:

     

    
      	
               
      

            	
              5.1

            	
              to
      provide either by itself or through third parties all of Teva’s
      requirements solely and exclusively to Teva for Testing Services ordered
      by licensed physicians in the Territory for persons located in the
      Territory; Rosetta shall not knowingly provide commercial Testing Services
      for a fee to physicians located in the Territory other than through Teva.
      All other activities for research purposes only in the Territories will be
      coordinated between Teva and Rosetta, and will be conducted according to
      applicable law and regulations. Rosetta shall have the right to perform
      the Testing Services via third parties subject to the following: (i)
      Rosetta being the responsible party; (ii) the Third Party shall have at
      least the same capabilities of Rosetta. In the event that Teva shall
      refuse the transfer of performance of Services to a third Party due to the
      fact that such third Party does not have the same capabilities of Rosetta,
      then this agreement at the sole discretion of Teva will be either
      terminated or modified to a non exclusive
  agreement.

            

    

     

    
      	
               
      

            	
              5.2

            	
              to
      assist and financially share all expenses relating to and/or resulting
      from conferences, seminars etc, all as will be mutually agreed (agreement
      to be made at the sole discretion of each party) and the details with
      respect to such events (including without limitation the details of the
      financial aspects of such event) will be added, from time to time, as an
      Appendix to this Agreement.

            

    

     

    
      	
               
      

            	
              5.3

            	
              to
      provide [***] to be [***] from signing this
  Agreement.

            

    

     

    
      	
               
      

            	
              5.4

            	
              to
      provide Teva with a minimum of [***] Testing Services for compassionate
      use programs, upon Teva's sole
discretion.

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              5.5

            	
              to
      provide all of Teva’s requirements for the Testing kits to collect the
      samples, and to deliver Test report and results within [***] of receipt of
      all relevant, complete and sufficient patient information and materials,
      including without limitation, Samples, from Teva. The report and results
      may be delivered to Teva by telefax or electronic
  mail.

            

    

     

    
      	
               
      

            	
              5.6

            	
              if
      paraffin blocks are provided, to return the remainder of the paraffin
      blocks to Teva within 1 month, of the conduct of the Tests, unless
      otherwise requested by Teva; the cost of such shipments shall be borne by
      Rosetta;

            

    

     

    
      	
               
      

            	
              5.7

            	
              if
      Teva provides a Sample, in accordance with the Instructions, and Rosetta
      performs the Testing Services on such Sample, but is unable to provide a
      report with respect to such Sample, then, at, Rosetta’s expense, Rosetta
      will either retest the Sample at its sole expense, or notify Teva that
      such Sample will not be retested. If such Sample will not be retested,
      Rosetta will not charge Teva for the testing of such
    Sample;

            

    

     

    
      	
               
      

            	
              5.8

            	
              If
      Teva provides a Sample, not according to the Instructions, Rosetta will
      notify Teva that such Sample will not be tested. Rosetta will charge Teva
      only for cost of kit shipment to Rosetta’s lab and cost of pathologist
      review (if applicable);

            

    

     

    
      	
               
      

            	
              5.9

            	
              if
      Teva provides a Sample according to the Instructions with respect thereto,
      and Rosetta performs the Testing Services on such Sample, and Rosetta
      becomes aware that there was an error made in the Testing Services which
      affected the Test results, then, at Rosetta’s expense, Rosetta will either
      retest the Sample at its sole expense, or notify Teva that such Sample
      will not be retested. If such Sample will not be retested, Rosetta will
      either not charge, or credit, as applicable, Teva for the Testing of such
      Sample.

            

    

     

    
      	
               
      

            	
              5.10

            	
              In
      order to ensure the fulfillment of Rosetta’s responsibilities and
      obligations in accordance with this Agreement, Rosetta is obligating to
      insure in its own responsibility itself and its employees, in a suitable
      and known insurance company commencing as of the Effective Day and shall
      maintain for the duration of this Agreement and [***] at its expense the
      following insurances, and to provide Teva with proof in a form of
      certificate of insurance attached as an Exhibit C of such
      insurances.

            

    

     

    
      	
               
      

            	
              5.11

            	
              Fulfilling
      the above mentioned insurance, based on this agreement and the payment of
      the insurance sum in accordance, are considered the basic condition of
      this agreement.

            

    

     

    
      	
               
      

            	
              5.12

            	
              None
      of the above insurance obligation will reduce Rosetta’s obligations, in
      accordance with this Agreement and in accordance with any
    law.

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    
      	
               
      

            	
              5.13

            	
              Rosetta
      is obligated to inform Teva about any cancellation and/or reduction in
      coverage of the Insurance policy and/or modification which shall
      negatively effect Teva pursuant to this
  Agreement

            

    

     

    
      	
               
      

            	
              5.14

            	
              Rosetta
      undertakes to provide Teva, free-of-charge, all reasonable support and
      marketing expertise, including copies of such promotional material as may
      be available from time to time, specific to the Testing Services necessary
      or useful for Teva in order to assist Teva in promoting and marketing the
      Testing Services in the Territory. Teva shall have the right to consult
      Rosetta regarding the nature and usage of these promotional materials.
      Teva will be responsible for all regulatory compliance of the promotional
      material in the Territory.

            

    

     

    
      	
               
      

            	
              5.15

            	
              Other
      than as expressly provided in this agreement, the Testing Services are
      provided ‘as is’ without warranty of any kind, whether express or implied,
      including without limitation warranties of merchantability, fitness for a
      particular purpose and non-infringements, and Rosetta disclaims any and
      all such warranties. Rosetta may decline to provide Testing Services on a
      specimen received from Teva that does not meet the
      Instructions.

            

    

     

    6.           TRADEMARKS

     

    
      	
               
      

            	
              6.1

            	
              The
      Testing Services shall be marketed by Teva under only such trademarks,
      service marks and/or other insignia of origin registered in Israel under
      Rosetta’s name or anyone on its behalf, as will be decided upon by
      Rosetta, in its sole discretion (the “Rosetta
  Marks”).

            

    

     

    
      	
               
      

            	
              6.2

            	
              During
      the term, and subject to the terms and conditions, of this Agreement and
      for the Territory only, Rosetta hereby grants to Teva a non-exclusive,
      non-transferable, limited license to use the Rosetta Marks solely in
      connection with the marketing of the Testing Services and the provision of
      Administrative Services in the Territory, provided
  that:

            

    

     

    
      	
               
      

            	
              6.2.1

            	
              Teva’s
      use of the Rosetta Marks must comply with the Trademark Usage Guidelines
      as provided by Rosetta to Teva and attached as an Exhibit A to this
      Agreement, as may be amended by Rosetta from time to time upon sufficient
      prior written notice to Teva.

            

    

     

    
      	
               
      

            	
              6.2.2

            	
              Teva
      shall ensure that all marketing materials or other documents on which the
      Rosetta Marks are placed by Teva (the “Marked Materials”) shall not
      reflect adversely upon the name, goodwill or reputation of Rosetta. Teva
      agrees that the Marked Materials shall be of such nature, style,
      appearance and quality as shall be adequate and suited to the protection
      of the Rosetta Marks and the goodwill associated
  therewith.

            

    

     

    
      	
               
      

            	
              6.2.3

            	
              Teva
      shall submit to Rosetta, free of cost, two samples of Marked Materials
      prior to the dissemination or distribution of the Marked Materials.
      Rosetta, in Rosetta’s sole discretion, shall have the right to review the
      Marked Materials submitted by Teva to confirm compliance with this
      Agreement. If Rosetta disapproves of any sample of the Marked Materials,
      Rosetta shall provide Teva with the specific reasons for such disapproval.
      Teva shall promptly make all such changes to the Marked Materials as
      Rosetta shall request to protect the value of the Rosetta
      Marks.

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    
    

     

    
      	
               
      

            	
              6.2.4

            	
              Teva
      shall not use the Rosetta Marks, or any part thereof, as part of or in
      combination with any other names or trademarks except with Rosetta’s prior
      written approval. Teva shall not use any confusingly similar or diluting
      mark, term or design, and shall not attempt to register or aid any third
      party in using or attempting to register any such mark, term or design.
      Teva shall not use any of the Rosetta Marks in any manner that indicates
      that it is using such mark other than as a
  licensee.

            

    

     

    
      	
               
      

            	
              6.2.5

            	
              If
      Teva refuses to submit such samples, after being requested by Rosetta to
      do so in writing or violates the provisions of this Clause 6 and/or the
      Rosetta Trademark Usage Guidelines and does not submit the samples, or
      cure the violation within 30 days after being notified of the same,
      Rosetta shall have the right to revoke the license granted to Teva
      pursuant to this Clause 6.

            

    

     

    
      	
               
      

            	
              6.2.6

            	
              The
      Rosetta Marks and the goodwill associated therewith are and remain
      Rosetta’s exclusive property. Teva shall acquire no right, title or
      interest in the Rosetta Marks or the goodwill associated therewith, other
      than the limited license and right to use the Rosetta Marks set forth in
      this Clause 6. All usage of the Rosetta Marks by Teva shall inure to
      Rosetta’s benefit. Teva shall not knowingly do or suffer to be done any
      act which would impair the Rosetta Marks or the goodwill associated
      therewith. Teva shall take any actions reasonably requested by Rosetta,
      and upon Rosetta sole expense, including the execution of instruments,
      that may be necessary or appropriate to register or otherwise confer or
      perfect Rosetta’s rights in the Rosetta Marks in the Territory in
      Rosetta’s name. Teva agrees to take no action inconsistent with Rosetta’s
      ownership of and interest in the Rosetta Marks, or assist any third party
      in doing any of the same.

            

    

     

    
      	
               
      

            	
              6.2.7

            	
              Teva
      was advised that the Rosetta Marks, are and shall remain Rosetta’s. Teva
      shall have no claim with regard to the said Rosetta Marks and shall not
      challenge Rosetta’s title to the Rosetta Marks or the validity of their
      registration, if they are
registered.

            

    

     

    
      	
               
      

            	
              6.2.8

            	
              Under
      no circumstances will anything in this Agreement be construed as granting,
      by implication, estoppel or otherwise, any licenses
      or rights in the Rosetta Marks not expressly granted to Teva in this
      Clause 6.

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    
    

     

    
      	
               
      

            	
              6.3

            	
              Rosetta
      is aware that “Teva” is a registered trade-name/mark of Teva (the “Teva
      Trademark”). It is agreed that the Teva Trademark shall not include the
      trademarks of Rosetta, whether registered or not (and visa
      versa).

            

    

     

    
      	
               
      

            	
              6.4

            	
              The
      Teva Trademark is or shall be registered in the Territory in Teva’s name,
      and at its expense.

            

    

     

    
      	
               
      

            	
              6.5

            	
              The
      Teva Trademark, whether registered or not, is and shall remain Teva’s.
      Rosetta shall have no claim with regard to the said Teva Trademark and
      shall not challenge Teva’s title to the Teva Trademark or the validity of
      its registration, if it is registered, even after termination of this
      Agreement for any reason.

            

    

     

    7.           PRICE AND TERMS OF
PAYMENT

     

    
      	
               
      

            	
              7.1

            	
              Teva
      shall pay to Rosetta a fee per Test for the Testing Services that Rosetta
      performs under this Agreement in the amount as set forth in Exhibit B. Any
      change based on the review shall be made only upon the written agreement
      of the parties to be provided at their sole
  discretion.

            

    

     

    
      	
               
      

            	
              7.2

            	
              Terms
      of payment - [***], except that Teva may withhold any amounts that are the
      subject of a good faith dispute until such dispute is resolved. All
      payments shall be made in full and without setoff, upon order, by bank
      transfer in U.S. dollars available at Rosetta’s U.S. bank, or otherwise as
      Rosetta may direct in advance.

            

    

     

    
      	
               
      

            	
              7.3

            	
              Teva
      shall be solely responsible for setting the pricing for its clients, and
      for collecting payment from its clients, for the Testing Services, and
      Teva’s delay in collecting, or failure to collect, shall not affect Teva’s
      obligation to pay Rosetta the applicable fees in any
  way.

            

    

     

    8.           TERMINATION

     

    
      	
               
      

            	
              8.1

            	
              Notwithstanding
      the above, and without prejudice to any other rights to which it may be
      entitled, either party may terminate this Agreement upon written notice of
      termination to the other party:

            

    

     

    
      	
               
      

            	
              8.1.1

            	
              if
      the other party is in material breach of any of the material terms hereof
      and fails to remedy such breach [***] of that party being notified of such
      breach; or

            

    

     

    
      	
               
      

            	
              8.1.1.1

            	
              if
      the other party is, admits to being or is declared insolvent, or voluntary
      or involuntary proceedings are instituted by or against it in bankruptcy,
      or receivership, or
      for a winding-up or for the dissolution or re-organization of its assets;
      or

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    
    

     

    
      	
               
      

            	
              8.1.1.2

            	
              based
      on medical safety or legal or regulatory
  reasons.

            

    

     

    
      	
               
      

            	
              8.2

            	
              In
      the event that the Agreement is terminated with respect to the Turkey
      territory then the Agreement will continue to be applicable with regard to
      the Israeli territory. In the event that the Agreement is terminated with
      regard to the Israeli Territory then the entire Agreement will be
      terminated, unless otherwise agreed between the Parties in
      writing.

            

    

     

    
      	
               
      

            	
              8.3

            	
              Termination
      for breach will have no effect on any performance obligations which have
      accrued up to the effective date of such
  termination.

            

    

     

    9.           EFFECTS OF
TERMINATION

     

    
      	
               
      

            	
              9.1

            	
              Termination
      of this Agreement howsoever caused shall be without prejudice to any other
      rights or liabilities accrued at the date of
  termination.

            

    

     

    
      	
               
      

            	
              9.2

            	
              Upon
      termination of this Agreement, all rights and licenses granted to Teva
      hereunder shall immediately terminate, and Teva shall immediately cease
      marketing and distributing the Testing Services, except as expressly
      provided in Clause 9.3.

            

    

     

    
      	
               
      

            	
              9.3

            	
              Upon
      termination of this Agreement, Teva shall notify Rosetta of any
      outstanding unstained slides or paraffin blocks it has in its possession,
      and Rosetta shall notify Teva of any outstanding Teva’s customers’ Tests
      it has, which have not been sent to Teva (whether completed or not).
      Subject to Teva’s advance payment of the applicable fees, Rosetta
      undertakes to complete the relevant Testing Services. Notwithstanding the
      foregoing, Rosetta will not be obligated to complete the Testing Services
      if Rosetta terminates this Agreement due to Teva’s breach or due to
      reasons of medical safety or legal or regulatory
  grounds.

            

    

     

    
      	
               
      

            	
              9.4

            	
              Neither
      party shall have any liability to the other for claims based on
      termination of this Agreement in accordance with Clause 8, including
      without limitation for compensation, reimbursement or damages for the loss
      of prospective profits, anticipated sales or goodwill. If a Party is
      entitled under local law or otherwise to any special payment or
      termination remedy or indemnity as a consequence of the expiration or
      termination of this Agreement, such Party hereby waives and disclaims, to
      the fullest extent permitted by law, any right to such payment, remedy or
      indemnity.

            

    

     

    
      	
               
      

            	
              9.5

            	
              Clauses
      1, 5.8, 6.5, 10, 11, 13, 18, 22 and 24 shall survive any expiration or
      termination of this Agreement.

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    
       

      
        	
                10.

              	
                HOLDING HARMLESS &
      INDEMNIFICATION

              

      

    

     

    
      	
               
      

            	
              10.1

            	
              Teva
      shall be solely responsible for any false or misleading statements, false
      or misleading representations or false or misleading warranties, whether
      oral or written, made by Teva to its clients. Without limiting the
      generality of the foregoing, Teva agrees and undertakes that it will not
      make any false or misleading statement, representation or warranty, oral
      or written, concerning the Tests and/or the Testing Services. In the event
      that Teva should make any false or misleading statements, representations
      or warranties, and claims should arise therefrom, Teva shall defend,
      indemnify and hold Rosetta, its affiliates, employees and agents
      (including successors and assigns) harmless from and against any and all
      costs, damages, expenses and liabilities arising out of or related to such
      statement, representation or
warranty.

            

    

     

    
      	
               
      

            	
              10.2

            	
              Rosetta
      shall be solely responsible for any false or misleading statements, false
      or misleading representations or false or misleading warranties made in
      the Promotional Materials provided by Rosetta to Teva. In the event that
      the Promotional Materials shall contain any false or misleading
      statements, representations or warranties, and claims should arise
      therefrom, Rosetta shall defend, indemnify and hold Teva, its affiliates,
      employees and agents (including successors and assigns) harmless from and
      against any and all costs, damages, expenses and liabilities arising out
      of or related to such statement, representation or
    warranty.

            

    

     

    
      	
               
      

            	
              10.3

            	
              Rosetta
      agrees to defend, indemnify and hold Teva, its affiliates, employees and
      agents (including successors and assignees) harmless from and against any
      claim by a third party and any and all costs, damages, expenses (including
      attorneys’ fees and other costs of litigation) and liabilities directly
      resulting therefrom arising out of infringement of third party
      intellectual property rights by the Testing Services, Rosetta’s negligence
      or willful misconduct in Rosetta’s provision of the Testing Services, or
      any breach by Rosetta of any of the terms of this Agreement, provided, however, that
      this indemnity shall not extend to any claim, demand, or legal action to
      the extent arising from any negligent act or omission or willful
      misconduct of Teva (including successors and assignees if
      applicable).

            

    

     

    
      	
               
      

            	
              10.4

            	
              Teva
      agrees to defend, indemnify and hold Rosetta, its affiliates, employees,
      agents (including successors and assignees) harmless from and against
      claim by a third party and any and all costs, damages, expenses (including
      attorneys’ fees and other costs of litigation) and liabilities directly
      resulting therefrom arising out of Teva’s negligence or willful misconduct
      in Teva’s provision of the Testing Services, or as result of any breach by
      Teva of any of the terms of this Agreement, provided, however, that
      this indemnity shall not extend to any claim, demand, or legal action
      to
      the extent arising from any negligent act or omission or willful
      misconduct of Rosetta (including successors and assignees if
      applicable).

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    
    

     

    
      	
               
      

            	
              10.5

            	
              The
      indemnity obligations under this Clause 10 are contingent upon: The party
      seeking indemnification (the “Indemnified Party”) (a) notifying the
      Indemnifying Party as soon as reasonably possible in reasonable detail of
      any claim, demand, action or proceeding for which indemnification is
      sought (the “Indemnified Claim”), (b) allowing the Indemnifying Party to
      control the defense and/or settlement of the Indemnified Claim, and (c)
      providing the Indemnifying Party with assistance in any defense and/or
      settlement thereof at the Indemnifying Party’s
  expense.

            

    

     

    
      	
               
      

            	
              10.6

            	
              The
      Indemnifying Party shall at its expense, assume the defense thereof using
      counsel reasonably acceptable to the Indemnified Party. The Indemnified
      Party shall have the right to participate at its own expense, in the
      defense and/or settlement of any third party claim, demand, action or
      proceeding. In connection with any such third party claim, demand, action
      or proceeding, the parties shall cooperate with each other and provide
      each other with access to relevant books and records in their possession.
      No such third party claim, demand, action or proceeding shall be settled
      without the prior written consent of the parties, which consent shall not
      be unreasonably withheld. The Indemnifying Party shall reimburse the
      Indemnified Party upon demand for any payments made based upon a
      conclusive judgment of any court of competent jurisdiction or pursuant to
      a bona fide compromise or settlement of claims agreed and accepted by the
      Indemnifying Party, in respect to any damages related to any claim under
      this Clause 10. In the event that the parties agree to settle a claim or
      action, such settlement shall not be publicized without the prior written
      consent of the parties, which consent shall not be unreasonably
      withheld.

            

    

     

    
      	
               
      

            	
              10.7

            	
              The
      provisions of this Clause shall survive the expiration or termination of
      this Agreement for any reason.

            

    

     

    11.           CONFIDENTIALITY

     

    
      	
               
      

            	
              11.1

            	
              All
      Proprietary Information disclosed by one Party to the other Party
      hereunder shall be maintained in confidence and shall not be disclosed to
      any Third Party or used for any purpose except as expressly permitted
      herein without the prior written consent of the Party that disclosed the
      Proprietary Information to the other Party for a period of five (5) years
      from the date hereof. The foregoing non-disclosure and non-use obligations
      shall not apply to the extent that such Proprietary
      Information:

            

    

     

    
      	
            	
              (i)

            	
              is
      known by the receiving Party at the time of its receipt, and not through a
      prior disclosure by the disclosing Party, as documented by contemporaneous
      written records;

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

          

        

         

      

      
         

        
          

        

      

      
         

      

    

    
       

       

      
        	
              	
                (ii)

              	
                is
      in the public domain or
knowledge;

              

      

    

     

    
      	
               
      

            	
              (iii)

            	
              is
      subsequently disclosed to a receiving Party by a Third Party who may
      lawfully do so and is not under an obligation of confidentiality to the
      disclosing Party; or

            

    

     

    
      	
               
      

            	
              (iv)

            	
              is
      developed by the receiving Party independently of Proprietary Information
      received from the other Party, as documented by contemporaneous research
      and development records.

            

    

     

    
      	
               
      

            	
              11.2

            	
              Notwithstanding
      Section 11.1, a Party receiving Proprietary Information of the other Party
      may disclose such Proprietary
Information:

            

    

     

    
      	
            	
              (i)

            	
              to
      governmental or other regulatory agencies in order to obtain patents, or
      to gain approval to conduct clinical trials or to market the Tests and/or
      the Testing Services to the extent permitted hereunder, but such
      disclosure may be only to the extent reasonably necessary to obtain such
      patents or authorizations;

            

    

     

    
      	
            	
              (ii)

            	
              to
      its respective agents, consultants, Affiliates, potential and actual
      sublicensees, and/or other Third Parties for the research and development,
      manufacturing and/or marketing of the Tests and/or the Testing Services
      (or for such Third Parties to determine their interests in performing such
      activities) on the condition that such Third Parties agree to be bound by
      the confidentiality obligations contained in this
    Agreement;

            

    

     

    
      	
               
      

            	
              (iii)

            	
              to
      actual or prospective acquirers or sources of financing on the condition
      that such Third Parties agree to be bound by the confidentiality
      obligations contained in this Agreement;
or

            

    

     

    
      	
               
      

            	
              (iv)

            	
              if
      required to be disclosed by law or court order, provided that, to the
      extent permitted by law, notice is promptly delivered to the disclosing
      Party in order to provide an opportunity to challenge or limit the
      disclosure obligations; provided, however, without limiting any of the
      foregoing, it is understood that either Party or its Affiliates may make
      disclosure of this Agreement and the terms hereof in any filings required
      by the SEC (or any applicable stock exchange or regulatory organization),
      may file this Agreement as an exhibit to any filing with the SEC (or any
      applicable stock exchange or regulatory organization) and may distribute
      any such filing in the ordinary course of its business. However, to the
      maximum extent allowable by SEC (or any applicable stock exchange or
      regulatory organization) rules and regulations, the Parties shall be
      obligated to maintain the confidentiality obligations set forth herein and
      shall redact any confidential information
      set forth in such filings as may be reasonably requested by the disclosing
      Party.

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    
    

     

    
      	
               
      

            	
              11.1

            	
              The
      provisions of this Clause shall survive the expiration or termination of
      this Agreement for any reason.

            

    

     

    12.           FORCE
MAJEURE

     

    
      	
               
      

            	
              12.1

            	
              The
      obligations of each party under this Agreement shall be suspended during
      the period of this Agreement and to the extent that such party is
      prevented or hindered from complying herewith by any cause beyond its
      reasonable control including (insofar as they are beyond such control but
      without prejudice to the generality of the foregoing expression) strike,
      act of God, war, riot, civil commotion, malicious damage, compliance with
      any law or governmental order, rule, regulation or direction, accident,
      breakdown of plant or machinery, fire, flood, storm, difficulty or
      increased expense in obtaining workmen, materials or transport or other
      circumstances affecting the supply of goods or of raw materials
      therefor.

            

    

     

    
      	
               
      

            	
              12.2

            	
              In
      the event of either party being so hindered or prevented, such party shall
      give notice of suspension as soon as reasonably possible to the other
      party stating the date and extent of such suspension and the cause
      thereof. The failure to give such notice shall forfeit the rights of such
      party to relief under this Clause.

            

    

     

    
      	
               
      

            	
              12.3

            	
              Any
      party whose obligations have been suspended as aforesaid shall resume the
      performance of such obligations as soon as reasonably possible after the
      removal of the cause and shall so notify the other party. In the event
      that such cause continues for more than six months either party may
      terminate this Agreement on thirty days notice to the other
      party.

            

    

     

    13.           GOVERNING
LAW

     

    This
Agreement shall be governed and interpreted according to the laws and
regulations of Israel. Any dispute between the parties shall be referred to the
applicable court of Tel Aviv, Israel.

     

    14.           ENTIRE
AGREEMENT

     

    This
Agreement constitutes the entire understanding between the parties hereto with
respect to the subject matter hereof and supersedes all prior and
contemporaneous agreements, negotiations and discussions between the parties
hereto relating thereto.

     

    15.           EXECUTION AND DELIVERY OF
THIS AGREEMENT

     

    
      	
               
      

            	
              15.1

            	
              Rosetta
      hereby represents and warrants that the execution and delivery by Rosetta
      of this Agreement and the performance by Rosetta of its obligations
      hereunder have been duly authorized by all necessary corporate
      action on the part of Rosetta, and do not conflict with the terms of any
      other contract, agreement, arrangement or understanding to which Rosetta
      is a party.

            

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    
      	
               
      

            	
            

    

     

    
      	
               
      

            	
              15.2

            	
              Teva
      hereby represents and warrants the execution and delivery by Teva of this
      Agreement and the performance by Teva of its obligations hereunder have
      been duly authorized by all necessary corporate action on the part of
      Teva, and do not conflict with the terms of any other contract, agreement,
      arrangement or understanding to which Teva is a
  party.

            

    

     

    16.           INDEPENDENT
CONTRACTORS

     

    All work
performed by the parties under this Agreement shall be as independent
contractors. None of the parties hereto are an agent, employee, partner,
representative or joint venturer of the other party and nothing in this
Agreement shall be construed to create such a relationship. None of the parties
hereto shall have the power or right to bind or obligate the other. The parties
hereby represent and warrant that each of them have the power and authority to
undertake the contractual commitments set forth in this Agreement and that the
execution of this Agreement and its performance of the services shall not
constitute a breach or default under any agreement which any of the parties have
entered into with any third party.

     

    17.           TERMS AND
CONDITIONS

     

    The
Testing Services supplied to Teva shall be supplied upon the terms and
conditions contained herein and any standard terms and conditions of sale or
conditions of purchases shall be of no effect, unless the parties otherwise
agree expressly and in a writing signed by both parties.

     

    18.           AMENDMENTS

     

    No
amendment or variation of this Agreement shall be effective unless in writing
and signed by duly authorized representatives of the parties.

     

    19.           ASSIGNMENT

     

    None of
the Parties hereto shall without the prior written consent of the other Parties,
assign, sub-license, sub-contract, delegate, charge or part with or otherwise
dispose of this Agreement or the benefit thereof or any right or obligation
hereunder or grant any sub-license or sub-contract, save that any Party shall be
entitled to assign this Agreement to one of its Affiliates. provided, however,
that either Party may assign this Agreement and its rights and obligations
hereunder without the consent of the other Party hereto to an Affiliate or in
connection with the transfer or sale of all or substantially all of its assets
related to Licensed Product or its business in the event of its merger or
consolidation or change in control or similar transactions. Any permitted
assignee shall assume all obligations of its assignor under this Agreement. and,
inter alia will be responsible to provide the other party with an amended
certificate of insurance in the exact wording as attached to this Agreement
Exhibit C. Any assignment or attempted assignment contrary to the provisions
hereof shall be null and void. In this respect, if the above mentioned
assignment will have a financial or commercial negative effect on Teva's
activities in Israel or abroad,
which such effect will be examined under a test of reasonability, Teva will have
the right to terminate this Agreement upon notice of termination to Rosetta
within thirty (30) days.

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

     

    20.           SEVERABILITY

     

    The
invalidity or unenforceability of any term of or any right arising pursuant to
this Agreement shall not in any way affect the remaining terms or rights unless
the invalid provision goes to the essence of this Agreement. Rosetta and Teva
hereby each undertakes to cooperate in good faith and to use all reasonable
endeavors to replace any legally unenforceable provision with (as far as
practicable) provisions which will effect for the parties the same commercial
results as were intended by the original provisions.

     

    21.           WAIVER

     

    The
failure of a party hereto to exercise or enforce any right under this Agreement
shall not be deemed to be a waiver thereof nor operate so as to bar the exercise
or enforcement thereof at any time or times thereafter.

     

    22.           SURVIVAL OF
INDEMNITY

     

    Each
indemnity in this Agreement is a continuing obligation separate and independent
from the other obligations of Rosetta and Teva and survives termination of this
Agreement.

     

    23.           NOTICES

     

    All
notices shall be in writing and shall be given by delivery by hand, by first
class mail postage prepaid, by air courier, or by transmission by fax to the
address or to the fax number of the relevant party set out at the beginning of
this Agreement or such other address or fax number as either party may notify to
the other from time to time and shall be addressed to the representatives of the
parties set out below:

     

    If to
Rosetta:

     

    Attention:
Mr. Ronen Tamir

    Chief
Commercialization Officer

    Rosetta
Genomics Inc.

    15
Exchange Place, suite 500, Jersey City NJ 07302

    Tel:
201.946.0561

    Fax:
201.946.0562

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    With a
copy to:

     

    General
Counsel

    Rosetta
Genomics Ltd.

    10 Plaut
St.

    Rehovot

    Tel:
+972.73.222.0700

    Fax:
+972.73.222.0701

     

    If to
Teva:

     

    Attention:
[***]

    [***]

    Teva
Pharmaceutical Industries Ltd.

    [***]

    [***]

    [***]

    [***]

    

    With a
copy to:

     

    Teva
Pharmaceutical Industries Ltd.

    5 Basel
Street, Petah Tiqva 49131, Israel

    Attention:
Legal Department

    Fax:
972-3-9267429

     

    The
parties shall inform the other within 7 Business Days of any change in address
or fax number. Any such notice given as aforesaid shall be deemed to have been
given (i) if mailed, 7 days after being dispatched by mail postage prepaid; (ii)
if by air courier, 4 days after delivery to the air courier company; (iii) if by
facsimile with confirmed transmission, 48 hours after transmission. An
additional copy of all notices issued by either party to the other relating to
breach or termination of this Agreement shall be sent, in cases of notices to
Rosetta, to Rosetta’s business development department, facsimile number
__________, and in cases of notices to Teva, to : 972-3-9267429.

     

    24.           LIMITATION OF
LIABILITY

     

    In no
event will either party be liable for any consequential, indirect, incidental,
punitive, exemplary or special damages under or related to this Agreement,
however caused and under any theory of liability, including without limitation,
breach of contract, breach of warranty or tort.

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    25.           PRESS
RELEASE

     

    Following
the execution of this Agreement the Parties will jointly word a press release
regarding the execution of this Agreement. The press release will be released as
a joint release of the two parties.

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    IN WITNESS WHEREOF, the
parties hereto have hereunto set their hands as of the date first set forth
above.

     

    ROSETTA
GENOMICS LTD.

     

    By: /s/ Tami
Fishman

    Title General
Counsel

    Date January 9,
2009

     

    By: /s/ Ranit
Aharonov

    Title EVP R
&D

    Date January 9,
2009

     

    

     

    TEVA
PHARMACEUTICAL INDUSTRIES LTD.

     

    By: /s/                                                                        

    [***]

    [***]

    [***] -
Teva Pharmaceutical Industries Ltd.

    

    Date

     

    By:
/s/                                                                         

    [***]

     

    Date

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    EXHIBIT
A

    [***]

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    EXHIBIT
B

    [***]

     

    
      	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            
	
              [***]

            	
              [***]

            	
              [***]

            

    

    

     

    
      
        
          Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

        

         

      

      
         

        
          

        

      

      
         

      

    

    EXHIBIT
C

    [***]

     

     

     

     

     

     

    
      Portions
of this Exhibit were omitted and have been filed separately with the Secretary
of the Commission pursuant to the Registrant’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934,
as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}]]